Preparation method of KRAS G12C mutant non-small cell lung cancer treatment medicine

Through a new method of 4-step reaction and one-step resistance isomer resolution, the preparation process of sotolasib was simplified, the problems of long routes and low yields in the existing technology were solved, and high optical purity and high quality were achieved The yield of sotolasibu is prepared with environmentally friendly characteristics.

CN118930538APending Publication Date: 2024-11-12BEIJING KANG LISHENG PHARMA TECH DEV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410996041.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing preparation method of sotolasib has problems with long routes and low yields, and more by-products are produced, which affects the optical purity and environmental friendliness of the product.

Method used

Using a new method of 4-step reaction and one-step resistance isomer resolution, the high optical purity is prepared by acylation docking reaction, cyclosynthesis reaction, chlorination reaction and debenzyl reaction, and specific catalysts and resolving agents. Sotolasibu, simplifies the synthesis route and reduces the production of by-products.

Benefits of technology

The route has been simplified, the optical purity and yield of the product have been improved, and the process conditions are mild, the environment is friendly, and it has industrial significance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930538A_ABST
    Figure CN118930538A_ABST
Patent Text Reader

Abstract

The invention provides a preparation method of a medicine for treating KRAS G12C mutant non-small cell lung cancer. The route development is beneficial to reducing the production cost of sotorasib and relieving the accessibility problem of sotorasib.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention belongs to the field of chemical drugs, and specifically relates to a new preparation method of Sotorasib, a drug for treating KRAS G12C mutant locally advanced or metastatic non-small cell lung cancer. Background Art

[0002] Lung cancer is a malignant tumor originating from the bronchial mucosa or glands of the lungs. It is one of the malignant tumors with the fastest growing incidence and mortality rate and the greatest threat to human health and life. In the past 50 years, many countries have reported that the incidence and mortality of lung cancer have increased significantly. The incidence and mortality of lung cancer in men rank first among all malignant tumors, and the incidence and mortality of women rank second. The number of people who die from lung cancer each year is about 1.5 million. Lung cancer mainly includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), of which NSCLC accounts for about 85% of all lung cancer cases. NSCLC is mainly composed of adenocarcinoma (40%), squamous cell carcinoma (30%), large cell carcinoma (10%) and other types of lung cancer (20%). At present, the diagnosis and treatment of lung cancer has entered the era of molecular pathology and multidisciplinary joint diagnosis and treatment. There are driver genes such as EGFR, K-RAS, ALK, ROS1, and c-MET in lung cancer. The occurrence and development of lung cancer are closely related to the mutation of the above genes. RAS mutations are found in one-third of human tumors. The RAS gene family includes three genes: NRAS, HRAS, and KRAS. RAS mutations mainly occur in the KRAS subtype. KRAS is a key mediator of the signal cascade that promotes cell growth and proliferation. It is the most common mutated oncogene in cancer, accounting for 85% of all RAS-related cancers. KRAS gene mutations are mainly concentrated at codons 12, 13, and 61, of which mutations at codon 12 account for more than 80%, including G12A, G12C, G12D, G12R, G12S, and G12V mutations. KRAS G12C mutations alone account for 44% of all KRAS mutations and are the most common in NSCLC, with an incidence of about 14%.

[0003] Sotolacib is an inhibitor of KRAS G12C that forms an irreversible covalent bond with the unique cysteine ​​of KRASG12C, locking the protein in an inactive state, thereby preventing downstream signaling without affecting wild-type KRAS. Sotolacib blocks KRAS signaling, inhibits cell growth, and promotes apoptosis only in KRAS G12C tumor cell lines. Sotolacib inhibits KRASG12C both in vitro and in vivo, with very low detectable off-target activity. In mouse tumor xenograft models, sotolacib treatment can lead to tumor regression and prolonged survival, and is associated with anti-tumor immunity in the KRAS G12C model. The launch of sotolacib has supplemented the treatment regimen for NSCLC. It has few adverse reactions and good tolerability, and is a potential NSCLC treatment drug.

[0004] The chemical name of Sotolacib is 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(prop-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one, CAS number: 2300966-23-6, which contains 2 chiral centers, one of which is formed by atropisomerism, and the specific structure is as follows:

[0005]

[0006] Prior art document patent CN201880047910 reports a synthetic route 1 of mixed configuration Sotolacib, which is as follows: Route 1:

[0007]

[0008] This route uses 2,6-dichloro-5-fluoronicotinic acid, 2-isopropyl-6-methylaniline, (S)-3-methylpiperazine-1-carboxylic acid tert-butyl ester, (2-fluoro-6-hydroxyphenyl) potassium trifluoroborate and acryloyl chloride as starting materials, and a mixed configuration of Sotolacib is prepared through 7 steps of reaction. The prior art document patent CN201980075080 adopts the same route, first chiral separation of the compound of formula 1 and then synthesis of Sotolacib, as follows:

[0009]

[0010] The prior art document patent WO2022246069 reports the synthesis routes 2 to 5 of Sotolacib, which are as follows:

[0011] Route 2:

[0012]

[0013] This route first performs chiral separation on the compound of formula 2 in route 1, and then reacts with (2-fluoro-6-hydroxyphenyl)boronic acid and 3-chloropropionyl chloride in four steps to prepare sotolacib.

[0014] Route 3, 4, 5:

[0015]

[0016] Route 3, 4, and 5 all use the compound of formula 1 in Route 1 as the starting material, which is first docked with (2-fluoro-6-hydroxyphenyl)boronic acid, and then prepared through different splitting and docking sequences to obtain Sotolacib.

[0017] The above five routes all have the problem of long routes and low yields. Summary of the invention

[0018] The object of the present invention is to overcome the deficiencies of the prior art and provide a method for preparing a drug for treating KRAS G12C mutant non-small cell lung cancer, and to provide a method for preparing sotolacizumab, the method being as follows:

[0019]

[0020] Step 1, preparing an intermediate compound of formula b by acylation and docking reaction of a compound of formula a and 2-isopropyl-6-methylaniline;

[0021] Step 2, the intermediate compound of formula b is subjected to a cyclization reaction to obtain the intermediate 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione;

[0022] Step 3, the intermediate 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione is resolved by a chiral resolving agent to obtain a single-configuration atropisomer 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1(M)-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione;

[0023] Step 4, the atropisomer 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1(M)-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione is first subjected to chlorination reaction, and then docked with (s)-1-propenyl-3-methylpiperazine to prepare the intermediate 6-fluoro-7-(2-fluoro-6-(benzyloxy)phenyl)-(1M)-1-[4-methyl-2-(prop-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one;

[0024] Step 5. The intermediate 6-fluoro-7-(2-fluoro-6-(benzyloxy)phenyl)-(1M)-1-[4-methyl-2-(prop-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one is subjected to debenzylation reaction to obtain sotolacib.

[0025] In the structures of the compounds of formula a and formula b, X is selected from chlorine, bromine or iodine.

[0026] The route for synthesizing Sotolacib in the present invention is different from that reported in the prior art documents CN201880047910, CN201980075080 and WO2022246069. The purpose of the present invention is to provide a novel method for preparing Sotolacib with high optical purity through four-step reaction and one-step atropisomer separation, which has the remarkable characteristics that the phenolic hydroxyl groups in the starting raw material compound of formula a and each intermediate are protected by benzyl groups, which greatly reduces the generation of by-products, the synthetic route is short, the reaction conditions are mild, the yield is high, the product has high optical purity, and it is environmentally friendly.

[0027] In the acylation docking reaction of step 1 of the present invention, X in the structure of the compound of formula a is a halogen, and the influence of different groups on the reaction activity and by-products is not much different; the acylating agent of the acylation docking reaction of step 1 of the present invention is carbonyldiimidazole (CDI); the molar feed ratio of the compound of formula a, 2-isopropyl-6-methylaniline and CDI is controlled to be 1:0.9-1.1:0.9-1.1, preferably 1:1:1, which can ensure complete reaction and less by-products.

[0028] In the structure of the compound of formula b in the cyclization reaction of step 2 of the present invention, X is a halogen, and the effects of different groups on the reaction activity and by-products are also not much different. The catalyst of the reaction is an organic base, and the organic base is selected from potassium bis(trimethylsilyl)amide (KHMDS), potassium bis(trimethylsilyl)amide (NaHMDS), potassium tert-butoxide, sodium tert-butoxide, sodium ethoxide or sodium methoxide, preferably potassium bis(trimethylsilyl)amide or potassium tert-butoxide; the molar feed ratio of the compound of formula b and the organic base is controlled to be 1:1.5-2.5, preferably 1:2, and the reaction temperature and reaction time are controlled to ensure that the reaction is complete and the by-products are less.

[0029] Step 3 of the present invention is a resolving agent for atropisomerization, wherein the resolving agent is D-(+)-di-p-methylbenzoyltartaric acid (D-(+)-DTTA) or D-(+)-dibenzoyltartaric acid (D-(+)-DBTA), and the intermediate 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3 The molar feed ratio of the H)-dione to the resolving agent is 1:1.5 to 2.5, preferably 1:2. The salt formation and resolving are first carried out in tetrahydrofuran solvent, and then the salt is dissolved to ensure that the high optical purity atropisomer 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1(M)-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione is obtained.

[0030] In step 4 of the present invention, the catalyst for the chlorination reaction of the atropisomer 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1(M)-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione is phosphorus oxychloride; the catalyst for docking with (s)-1-propenyl-3-methylpiperazine is an organic base selected from triethylamine, N,N-diisopropylethylamine, N-methylmorpholine or dimethylaminopyridine; controlling 7-(2 The molar feed ratio of (benzyloxy)-6-fluorophenyl)-6-fluoro-1(M)-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, (s)-1-propenyl-3-methylpiperazine, phosphorus oxychloride and organic base is 1:1.1-1.5:1.1-1.5:2-4, preferably 1:1.2:1.2:3, and controlling the reaction temperature and reaction time can ensure complete reaction with less by-products.

[0031] The catalyst for the debenzylation reaction in step 5 of the present invention is a palladium catalyst, and the palladium catalyst is selected from Pd / C or Pd(OH) 2 / C; controlling the molar feed ratio of the intermediate (intermediate 6-fluoro-7-(2-fluoro-6-(benzyloxy)phenyl)-(1M)-1-[4-methyl-2-(prop-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one and the palladium catalyst to be 1:0.005 to 0.02, preferably 1:0.01, and continuously passing hydrogen, which can completely debenzylate, with high yield and less by-products.

[0032] The present invention provides a new method for preparing sotolacib with a short route, high yield, high product optical purity and environmental friendliness. The method is of great significance for the industrialization of sotolacib and can benefit from it. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 :Process route diagram of the present invention Specific implementation methods

[0035] The technical solutions in the embodiments of the present invention will be described in detail below in conjunction with the embodiments of the present invention. However, the following embodiments are only used to understand the present invention and cannot limit the present invention. The present invention can be implemented in a variety of different ways as defined and covered by the claims.

[0036] The following will further illustrate the synthesis method of Sotolacib intermediate formula b and the advantages of the method in conjunction with Examples 1 to 9 of the present invention.

[0037] Example 1: Synthesis of 6-(2-(benzyloxy)-6-fluorophenyl)-2-chloro-5-fluoro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide (Formula bI)

[0038]

[0039] 6-(2-(Benzyloxy)-6-fluorophenyl)-2-chloro-5-fluoronicotinic acid (Formula aI, 187.9 g, 0.5 mol) and 1 L of dimethylformamide were added to a three-necked flask, stirred and cooled to 0°C, and N'N-carbonyldiimidazole (CDI, 81.1 g, 0.5 mol) was added in batches at a temperature below 20°C. The mixture was stirred at room temperature for 2 h until the reaction was complete, and 2-isopropyl-6-methylaniline (74.6 g, 0.5 mol) was added in batches at a temperature below 20°C. After the addition was completed, the temperature was controlled at 20-30°C and the reaction was continued with stirring for 4 h until the reaction was complete. The mixture should be complete, 2 L of ethyl acetate and 1.5 L of water were added, and the mixture was stirred and separated. The organic phase was washed with 1.5 L of water, 1 L of 10% sodium bicarbonate solution, 1.5 L of water, and 1.5 L of water in sequence, and dried over anhydrous sodium sulfate. Most of the solvent was concentrated under reduced pressure, and 400 ml of n-hexane was added to disperse the residue by stirring. The residue was filtered and the filter cake was dried to obtain 6-(2-(benzyloxy)-6-fluorophenyl)-2-chloro-5-fluoro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide (Formula bI, 239.7 g, yield 87%), Ms m / z 551.2 (M+1).

[0040] Example 2: Synthesis of 6-(2-(benzyloxy)-6-fluorophenyl)-2-bromo-II-5-fluoro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide (Formula b-II)

[0041]

[0042] Add 6-(2-(Benzyloxy)-6-fluorophenyl)-2-bromo-5-fluoronicotinic acid (Formula a-II, 210.1 g, 0.5 mol) and 1 L of dimethylformamide into a dry three-necked flask, stir and cool to 0°C, add N'N-carbonyldiimidazole (CDI, 81.1 g, 0.5 mol) in batches at a temperature below 20°C, stir at room temperature for 2 h until the reaction is complete, then add 2-isopropyl-6-methylaniline (74.6 g, 0.5 mol) in batches at a temperature below 20°C, and after the addition, control the temperature at 20-30°C and continue stirring for 4 h. After the reaction was complete, 2 L of ethyl acetate and 1.5 L of water were added, and the mixture was stirred and separated. The organic phase was washed with 1.5 L of water, 1 L of 10% sodium bicarbonate solution, 1.5 L of water, and 1.5 L of water in sequence, and dried over anhydrous sodium sulfate. Most of the solvent was concentrated under reduced pressure, and the residue was dispersed by stirring with 400 ml of n-hexane, filtered, and the filter cake was dried to obtain 6-(2-(benzyloxy)-6-fluorophenyl)-2-chloro-5-fluoro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide (Formula b-II, 253.1 g, yield 85%), Ms m / z 595.2 (M+1).

[0043] Example 3: Synthesis of 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

[0044]

[0045] 6-(2-(Benzyloxy)-6-fluorophenyl)-2-chloro-5-fluoro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide (Formula bI, 220.4 g, 0.4 mol) and 1.6 L of tetrahydrofuran were added to a dry three-necked flask, stirred and cooled to 0°C, and a solution of potassium bis(trimethylsilyl)amide (KHMDS, 159.6 g, 0.8 mol) in tetrahydrofuran (600 ml) was added dropwise at a temperature below 10°C. After the addition was completed, the mixture was naturally warmed to room temperature, and the reaction was continued with stirring for 1 h. The reaction was terminated and saturated ammonium chloride solution was added. The reaction was quenched with 1 L of liquid, 2.5 L of ethyl acetate and 1 L of water were added, and the pH was adjusted to 4-5 with hydrochloric acid under stirring, filtered, separated, and the organic phase was washed twice with water (1.5 L / time), dried over anhydrous sodium sulfate, and the organic phase was concentrated under reduced pressure to remove 90% of the solvent. 1 L of petroleum ether was added to the residue to precipitate a large amount of solid, which was filtered and dried to obtain 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (170.8 g, yield 83%), Ms m / z 515.3 (M+1). 1 HNMR (400MHz, CDCl 3 ): δ1.32(d, 6H), δ2.32(s, 3H), 3.46(q, 1H), 5.18(s, 1H), 6.90(d, 1H), 7.18(t, 1H), 7.30-7.52(m, 7H), 7.63(d, 1H), 8.26(d, 1H).

[0046] Example 4: Synthesis of 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

[0047]

[0048] 6-(2-(Benzyloxy)-6-fluorophenyl)-2-chloro-5-fluoro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide (Formula bI, 220.4 g, 0.4 mol) and 1.6 L of tetrahydrofuran were added to a dry three-necked flask, stirred and cooled to 0°C, and a solution of potassium tert-butoxide (t-BuOK, 89.8 g, 0.8 mol) in tetrahydrofuran (600 ml) was added dropwise with the temperature controlled below 10°C. After the addition was completed, the mixture was naturally warmed to room temperature, and the reaction was continued with stirring for 1 h. The reaction was terminated and ethyl acetate was added. 2.5L and 2L of water, adjust the pH to 4-5 with hydrochloric acid under stirring, separate the liquids, stir and filter, separate the liquids, wash the organic phase with water twice (1.5L / time), dry over anhydrous sodium sulfate, and concentrate the organic phase under reduced pressure to remove 90% of the solvent. Add 1L of petroleum ether to the residue to precipitate a large amount of solid, filter and dry to obtain 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (172.9 g, yield 84%), Ms m / z 515.3 (M+1).

[0049] Example 5: Preparation of 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1(M)-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

[0050]

[0051] 7-(2-(Benzyloxy)-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (308.7 g, 0.6 mol), D-(+)-di-p-methylbenzoyltartaric acid (463.6 g, 1.2 mol) and 2.2 L of tetrahydrofuran were placed in a dry three-necked flask, heated to reflux and stirred to dissolve, cooled slightly, 30 g of activated carbon was added, and refluxed for 30 min. Filter, transfer the filtrate to a three-necked flask and continue to heat to reflux, add 800 ml of n-hexane under reflux, slowly cool to 60°C, add seed crystals, control the temperature at 60°C and stir to crystallize for 5 hours, control the temperature at 50-60°C and slowly add 800 ml of n-hexane, naturally cool to room temperature and continue crystallization for 12 hours, filter, rinse the filter cake with 500 ml of tetrahydrofuran-n-hexane (10:7) mixed solvent, and dry to obtain M-configuration D-(+)-DTTA salt (2:1) (186.8 g, 0.264 mol).

[0052] The above-mentioned M-configuration D-(+)-DTTA salt (2:1), 1.5 L of ethyl acetate and 0.2 mol / L sodium bicarbonate solution (1.32 L, 0.264 mol) were placed in a three-necked flask, stirred at room temperature until completely dissolved, separated, the organic phase was washed with 1 L of water, dried over anhydrous sodium sulfate, and 4 / 5 of the solvent was concentrated under reduced pressure. 900 ml of n-hexane was added under stirring, and the mixture was cooled to 0° C. and continued to stir for 4 h. The mixture was filtered and dried to obtain 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1(M)-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (132.7 g, yield 86%) with a chemical purity of 99.1% and an optical purity of 99.8%.

[0053] Example 7: Synthesis of 6-fluoro-7-(2-fluoro-6-(benzyloxy)phenyl)-(1M)-1-[4-methyl-2-(prop-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one

[0054]

[0055] 7-(2-(Benzyloxy)-6-fluorophenyl)-6-fluoro-1(M)-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (102.9 g, 0.2 mol) and 1 L of toluene were placed in a dry three-necked flask, phosphorus oxychloride (36.8 g, 0.24 mol) was added dropwise at room temperature, and the reaction was continued for 30 min. The mixture was cooled to 0°C, 500 ml of water was added dropwise at a temperature below 10°C, and the mixture was stirred for separation. The organic phase was washed with 1 L of saturated sodium bicarbonate solution, 1 L of water, and 1 L of water in sequence, and dried over anhydrous sodium sulfate. The organic phase was transferred to a dry three-necked flask, cooled to 0-10°C, and (s)-1-propenyl-3-methylpiperidin was added. Oxazine (37.0 g, 0.24 mol) and triethylamine (60.7 g, 0.6 mol) were added, the temperature was controlled at 0-10°C and stirred for reaction for 20 min, 0.5 L of ethyl acetate and 1.2 L of water were added, the liquid was separated by stirring, and the organic phase was washed with water twice (1 L / time), dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was added with n-hexane and stirred and dispersed, filtered, and the filter cake was dried to obtain 6-fluoro-7-(2-fluoro-6-(benzyloxy)phenyl)-(1M)-1-[4-methyl-2-(prop-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one (127.5 g, 98%), Ms m / z 651.3 (M+1).

[0056] Example 8: Synthesis of Sotolacib

[0057]

[0058] 6-Fluoro-7-(2-fluoro-6-(benzyloxy)phenyl)-(1M)-1-[4-methyl-2-(prop-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one (117.1 g, 0.18 mol) 5% Pd / C (8.5 g, 55% water, 1.8 mmol) and 1.5 L of anhydrous ethanol were added to a three-necked flask. Hydrogen was continuously introduced under stirring, the temperature was controlled at 20-30°C for 8 hours, the reaction was terminated, the mixture was heated to 40-50°C, filtered while hot, the filtrate was concentrated under reduced pressure to remove 4 / 5 of the solvent, the residue was heated to reflux and completely dissolved, 5 g of activated carbon was added and refluxed for 30 minutes, filtered while hot, the filtrate was transferred to a three-necked flask and heated to reflux and dissolved, the heating was stopped, 800 ml of water was slowly added dropwise under stirring, the mixture was cooled to 10-20°C for crystallization for 12 hours, and sotolacib (83.8 g, 83%) was obtained by filtration and drying, Ms m / z 561.3 (M+1), chemical purity 99.4%, and optical purity 99.9%. 1 HNMR (400MHz, CDCl 3 )δ0.95(d,3H),1.09(d,3H),1.37(d,3H),1.93(s,3H),2.65-2.75(m,1H),3.10-3.30(m,1H),3.45-3.80

[0059] (m,2H),3.96-4.20(m,1H),4.25-4.47(m,2H),4.93(s,1H),5.75-5.82(m,1H),6.23(d,1H),6.70(t,1H), 6.76(d,1H),6.88(d,1H),7.20(d,1H),7.24-7.33(m,1H),8.25-8.36(m,1H),8.40(d,1H),10.21(s,1H).

[0060] Compared with the synthesis method of the sotolacib intermediate compound b reported in the prior art documents, Examples 1-9 of the present invention have the advantages of short route, high yield, high product optical purity, and environmental friendliness. The intermediate compound b is of great significance to the industrialization of sotolacib.

[0061] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for preparing a drug for treating KRAS G12C mutant non-small cell lung cancer, It is characterized in that The method is: Step 1, the compound of formula a and 2-isopropyl-6-methylaniline are subjected to acylation docking reaction to obtain an intermediate compound of formula b; Step 2, the intermediate compound of formula b is subjected to a cyclization reaction to obtain the intermediate 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione; Step 3, the intermediate 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione is resolved by a chiral resolving agent to obtain a single-configuration atropisomer 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1(M)-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione; Step 4, the atropisomer 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1(M)-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione is first subjected to chlorination reaction, and then docked with (s)-1-propenyl-3-methylpiperazine to prepare the intermediate 6-fluoro-7-(2-fluoro-6-(benzyloxy)phenyl)-(1M)-1-[4-methyl-2-(prop-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one; Step 5. The intermediate 6-fluoro-7-(2-fluoro-6-(benzyloxy)phenyl)-(1M)-1-[4-methyl-2-(prop-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one is subjected to debenzylation reaction to obtain sotolacib. In the structures of the compounds of formula a and formula b, X is selected from chlorine, bromine or iodine.

2. The preparation method according to claim 1, It is characterized in that The acylating agent for the acylation docking reaction in step 1 is carbonyldiimidazole (CDI); the molar feed ratio of the compound of formula a, 2-isopropyl-6-methylaniline and CDI is 1:0.9-1.1:0.9-1.1, preferably 1:1:

1.

3. The preparation method according to claim 1, It is characterized in that The catalyst for the cyclization reaction in step 2 is an organic base, which is selected from potassium bis(trimethylsilyl)amide (KHMDS), potassium bis(trimethylsilyl)amide (NaHMDS), potassium tert-butoxide, sodium tert-butoxide, sodium ethoxide or sodium methoxide, preferably potassium bis(trimethylsilyl)amide or potassium tert-butoxide; the molar feed ratio of the compound of formula b to the organic base is 1:1.5-2.5, preferably 1:

2.

4. The preparation method according to claim 1, It is characterized in that The resolving agent for the atropisomers in step 3 is D-(+)-di-p-methylbenzoyltartaric acid (D-(+)-DTTA) or D-(+)-dibenzoyltartaric acid (D-(+)-DBTA), and the molar feed ratio of 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione to the resolving agent is 1:1.5 to 2.5, preferably 1:

2.

5. The preparation method according to claim 1, It is characterized in that The catalyst for the chlorination reaction of the atropisomer 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1(M)-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione in step 4 is phosphorus oxychloride; the catalyst for docking with (s)-1-propenyl-3-methylpiperazine is an organic base selected from triethylamine, N,N-diisopropylethylamine, N-methylmorpholine The molar feed ratio of 7-(2-(benzyloxy)-6-fluorophenyl)-6-fluoro-1(M)-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, (s)-1-propenyl-3-methylpiperazine, phosphorus oxychloride and organic base is 1:1.1-1.5:1.1-1.5:2-4, preferably 1:1.2:1.2:

3.

6. The preparation method according to claim 1, It is characterized in that The catalyst for the debenzylation reaction in step 5 is a palladium catalyst, and the palladium catalyst is selected from Pd / C or Pd(OH) 2 / C; the molar feed ratio of the intermediate (intermediate 6-fluoro-7-(2-fluoro-6-(benzyloxy)phenyl)-(1M)-1-[4-methyl-2-(prop-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one to the palladium catalyst is 1:0.005 to 0.02, preferably 1:0.01.